Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): Results from the Bladder Cancer Advocacy Network (BCAN) survey

BJU International

Volumn 110, Issue 7, 2012, Pages 967-972

  Nielsen, Matthew E ^a   Smith, Angela B ^a   Pruthi, Raj S ^a   Guzzo, Thomas J ^b   Amiel, Gilad ^c   Shore, Neal ^d   Lotan, Yair ^e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Grand Strand Urology   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

bladder cancer; intravesical therapy; patterns of care; physician survey

Indexed keywords

BCG VACCINE; INTERFERON; MITOMYCIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; IMMUNOLOGICAL ADJUVANT;

ARTICLE; BLADDER BIOPSY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CLINICAL PRACTICE; CONTROLLED STUDY; CYSTOSCOPY; HEALTH SURVEY; HUMAN; MAINTENANCE THERAPY; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; SELF REPORT; THERAPY EFFECT; TRANSURETHRAL RESECTION; TUMOR VOLUME; BLADDER TUMOR; IMMUNOTHERAPY; INTRAVESICAL DRUG ADMINISTRATION; METHODOLOGY; UROLOGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BCG VACCINE; HUMANS; IMMUNOTHERAPY; MITOMYCIN; PHYSICIAN'S PRACTICE PATTERNS; URINARY BLADDER NEOPLASMS; UROLOGY;

EID: 84871699562     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11060.x     Document Type: Article

References (17)

1. Lamm DL, Blumenstein BA, Crissman JD, et al,. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124-9
2. Sylvester RJ, Oosterlinck W, van der Meijden AP,. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171: 2186-90
3. Shelley MD, Kynaston H, Court J, et al,. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001; 88: 209-16
4. Hall MC, Chang SS, Dalbagni G, et al,. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178: 2314-30
5. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J,. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-14
6. Smith JA Jr, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG,. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 1999; 162: 1697-701
7. Hollenbeck BK, Ye Z, Dunn RL, Montie JE, Birkmeyer JD,. Provider treatment intensity and outcomes for patients with early-stage bladder cancer. J Natl Cancer Inst 2009; 101: 571-80
8. Snyder C, Harlan L, Knopf K, Potosky A, Kaplan R,. Patterns of care for the treatment of bladder cancer. J Urol 2003; 169: 1697-701
9. Madeb R, Golijanin D, Noyes K, et al,. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer 2009; 115: 2660-70
10. Joudi FN, Smith BJ, O'Donnell MA, Konety BR,. Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis. Urology 2003; 62: 1083-8
11. O'Leary MP, Gee WF, Holtgrewe HL, et al,. 1999 American Urological Association Gallup Survey: changes in physician practice patterns, treatment of incontinence and bladder cancer, and impact of managed care. J Urol 2000; 164: 1311-6
12. Strope SA, Ye Z, Hollingsworth JM, Hollenbeck BK,. Patterns of care for early stage bladder cancer. Cancer 2010; 116: 2604-11
13. Dalbagni G, Rechtschaffen T, Herr HW,. Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to bacillus Calmette-Guerin therapy? J Urol 1999; 162: 708-9
14. Murakami T, Ebara S, Saika T, et al,. Routine transurethral biopsy of the bladder is not necessary to evaluate the response to bacillus calmette-guerin therapy. Acta Med Okayama 2007; 61: 341-4
15. Highshaw RA, Tanaka ST, Evans CP, deVere White RW,. Is bladder biopsy necessary at three or six months post BCG therapy? Urol Oncol 2003; 21: 207-9
16. Flum DR, Fisher N, Thompson J, Marcus-Smith M, Florence M, Pellegrini CA,. Washington State's approach to variability in surgical processes/Outcomes: Surgical Clinical Outcomes Assessment Program (SCOAP). Surgery 2005; 138: 821-8
17. AUA. American Urological Association Member Profile. Available at: http://www.auanet.org/content/about-us/members/membersprofile.pdf. Accessed 26 January 2010